BURLINGTON, Mass., Nov. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, among a range of current and emerging therapies, surveyed endocrinologists in the United States and Europe indicate that Eli Lilly's novel glucagon-like peptide 1 (GLP-1) receptor agonist dulaglutide has the optimal balance of efficacy, safety and tolerability, and delivery attributes for the treatment of patients with type 2 diabetes who are inadequately controlled with metformin. In the crowded type 2 diabetes second-line treatment landscape, dulaglutide's delivery attributes give it a slight edge over other currently available and emerging therapies, which include agents from the following drug classes: GLP-1 receptor agonists, dipeptidyl peptidase-IV inhibitors and sodium glucose cotransporter 2 inhibitors.
The 2013 DecisionBase report entitled Type 2 Diabetes: When Metformin Has Lost the Battle for Glycemic Control, What Antidiabetic Agents Win Endocrinologists' Backing? also finds that surveyed endocrinologists are most compelled by drugs that reduce glycated hemoglobin A1c (HbA1c) levels. However, the high price of novel type 2 diabetes agents could offset endocrinologists' receptivity to such agents. Payers also indicate that they would only accommodate high price premiums in the presence of substantial improvements in efficacy. In addition, U.S. and European endocrinologists regard reductions in bodyweight as an important unmet need, reflecting the high prevalence of excess weight in the type 2 diabetes population.
The findings also reveal that surveyed endocrinologists consider many of the current and emerging type 2 diabetes therapies to provide improvements over the current patient-share leader, Merck's Januvia, despite this agent's reputation as having a good risk-benefit profile. However, the emerging type 2 diabetes therapies, in general, do not provide distinct advantages over the currently available agents.
"With the wider range of treatments available and the benefits of individualizing therapy increasingly being recognized, the decisions facing prescribers and payers regarding second-line antidiabetic agents are more challenging than ever," said Decision Resources Analyst Tim Blackstock, M.B., Ch.B. "As yet, no agent has met the medical needs that have been identified, and significant opportunity remains in the type 2 diabetes market."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
|SOURCE Decision Resources|
Copyright©2012 PR Newswire.
All rights reserved